Questions Roll In As UDI Expands In US; Debate Over System Adoption Continues
This article was originally published in Clinica
While the US FDA's requirements relating to unique device identification (UDI) first took effect in 2014, the UDI mandate remains a dynamic issue for the medtech industry as more and more devices become subject to UDI labeling and database submissions each year.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.